There's an exclusive group of companies in the stock market that stand out because they've got what billionaire investor Warren Buffett calls economic moats. Like medieval castles, their profits are fortified by impregnable business mo...
|Type||Buy / Hold / Sell|
|Year End 30th Jun||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
Latest News & Insights for BVXP
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that these stocks are hard to find - but there are signs that Bioventix LON:BVXP c...
Given that widespread uncertainty in the economy and the stock market is likely to endure for many months, it pays to know that you're investing in high-quality stocks, rather than speculative ones. This means safe, profitable companie...
It's a good time to be a shareholder in Bioventix (LON:BVXP): as the share approaches its 52-week high, holders may be wondering whether to sell and take the profit, or buy more and ride the uptrend. Shares in Bioventix are currently t...
Shares in Bioventix (LON:BVXP) are currently trading close to a 52 week high, with the share price up by around 0.23% - to 4300 - over the past week. On a one-month basis, the Bioventix share price has risen by 6.54%. For investors hol...
Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The Company offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company also supplies antibody products and services to multinational clinical diagnostics companies. The Company sells its products through direct sales and through distributors.
- 7 Romans Business Park, East Street, FARNHAM, GU9 7SX
- +44 1252728001
- James Cowper Kreston
Latest News for BVXP
Upcoming Events for BVXP
Full Year 2022 Bioventix PLC Earnings Release
Bioventix PLC Annual Shareholders Meeting
As of Today at 07:03 UTC, shares in Bioventix are trading at 3,450.00p. This share price information is delayed by 15 minutes.
Shares in Bioventix last closed at 3,450.00p and the price had moved by -13.1% over the past 365 days. In terms of relative price strength the Bioventix share price has underperformed the FTSE All Share Index by -10.33% over the past year.
There is no consensus recommendation for this security.
The Bioventix dividend yield is 4.41% based on the trailing twelve month period.
Last year, Bioventix paid a total dividend of £1.52, and it currently has a trailing dividend yield of 4.41%. We do not have any data on when Bioventix is to next pay dividends.
We do not have data on when Bioventix is to next pay dividends. The historic dividend yield on Bioventix shares is currently 4.41%.
To buy shares in Bioventix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3,450.00p, shares in Bioventix had a market capitalisation of £178.42m.
Here are the trading details for Bioventix:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BVXP
Based on an overall assessment of its quality, value and momentum Bioventix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bioventix is 4,331.39p. That is 25.55% above the last closing price of 3,450.00p.
Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of £1.27 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventix. Over the past six months, its share price has outperformed the FTSE All Share Index by +8.33%.
As of the last closing price of 3,450.00p, shares in Bioventix were trading +0.15% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioventix PE ratio based on its reported earnings over the past 12 months is 26.74. The shares last closed at 3,450.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioventix's management team is headed by:
- Ian Nicholson - NEC
- Peter Harrison - CEO
- Bruce Hiscock - CFO
- Treena Turner - NED
- Nick McCooke - NID